دورية أكاديمية
أعرض في EDS

Circulating Tumor Cells in Desmoid Tumors: New Perspectives.

التفاصيل البيبلوغرافية
العنوان: Circulating Tumor Cells in Desmoid Tumors: New Perspectives.
المؤلفون: Braun AC; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Campos FAB; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Abdallah EA; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Ruano APC; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Medina TDS; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Tariki MS; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Pinto FFE; Department of Orthopedics, A. C. Camargo Cancer Center, São Paulo, Brazil., de Mello CAL; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Chinen LTD; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil.
المصدر: Frontiers in oncology [Front Oncol] 2021 Sep 14; Vol. 11, pp. 622626. Date of Electronic Publication: 2021 Sep 14 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Introduction: Desmoid tumor (DT) is a rare neoplasm with high local recurrence rates, composed of fibroblastic cells that are characterized by the expression of key molecules, including the intermediate filament vimentin, cyclooxygenase-2 (COX-2), and nuclear β-catenin, and lack of epithelial markers. Circulating tumor cells (CTCs) isolated from the peripheral blood of patients with sarcomas and other neoplasms can be used as early biomarkers of tumor invasion and dissemination. Moreover, CTCs can also re-colonize their tumors of origin through a process of "tumor self-seeding."
Objectives: We aimed to identify CTCs in the peripheral blood of patients with DT and evaluate their expression of β-catenin, transforming growth factor receptor I (TGF-βRI), COX-2, and vimentin proteins.
Material and Methods: We conducted a prospective study of patients with initial diagnosis or relapsed DT with measurable disease. Blood samples from each patient were processed and filtered by ISET ® (Rarecells, France) for CTC isolation and quantification. The CTC expression of β-catenin, COX-2, TGF-βRI, and vimentin was analyzed by immunocytochemistry (ICC).
Results: A total of 18 patients were included, and all had detectable CTCs. We found a concordance of β-catenin expression in both CTCs and primary tumors in 42.8% (6/14) of cases by using ICC and immunohistochemistry, respectively.
Conclusions: Our study identified a high prevalence of CTCs in DT patients. Concordance of β-catenin expression between primary tumor and CTCs brings new perspectives to assess the dynamics of CTCs in the blood compartment, opening new avenues for studying the biology and behavior of DT. In addition, these results open the possibility of using CTCs to predict DT dynamics at the time of disease progression and treatment. Further studies with larger sample sizes are needed to validate our findings.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Braun, Campos, Abdallah, Ruano, Medina, Tariki, Pinto, de Mello and Chinen.)
References: Cell. 2014 Aug 28;158(5):1110-1122. (PMID: 25171411)
J Thorac Dis. 2013 Oct;5(5):593-9. (PMID: 24255771)
Eur J Cancer. 2016 May;58:90-6. (PMID: 26974708)
Transl Oncol. 2021 Jan;14(1):100932. (PMID: 33157516)
Oncol Lett. 2018 May;15(5):7376-7382. (PMID: 29725451)
Annu Rev Pharmacol Toxicol. 2009;49:265-90. (PMID: 18851701)
Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. (PMID: 16531064)
Cancer Biol Ther. 2018 Jun 3;19(6):454-460. (PMID: 29394136)
Oncogene. 2020 Aug;39(34):5589-5600. (PMID: 32651460)
Oncologist. 2019 Sep;24(9):e854-e863. (PMID: 30846515)
Chem Rev. 2011 Oct 12;111(10):5821-65. (PMID: 21942677)
Cancer. 2007 Jun 25;111(3):166-72. (PMID: 17477374)
Cancer Biol Ther. 2015;16(9):1289-95. (PMID: 26252055)
Cancer. 2010 May 1;116(9):2258-65. (PMID: 20187095)
PLoS One. 2017 Jan 6;12(1):e0169427. (PMID: 28060956)
Surg Oncol Clin N Am. 2016 Oct;25(4):803-26. (PMID: 27591500)
Nature. 2016 Jan 21;529(7586):298-306. (PMID: 26791720)
Curr Oncol Rep. 2021 Mar 14;23(4):41. (PMID: 33719012)
Annu Rev Med. 2013;64:131-44. (PMID: 23020877)
Cancers (Basel). 2020 Jul 09;12(7):. (PMID: 32660036)
Cell. 2009 Dec 24;139(7):1315-26. (PMID: 20064377)
Ann Surg Oncol. 2012 Dec;19(13):4036-42. (PMID: 22972507)
Cancer Lett. 2007 Aug 18;253(2):180-204. (PMID: 17314005)
Histopathology. 2011 Aug;59(2):336-40. (PMID: 21884214)
J Thorac Oncol. 2012 Feb;7(2):306-15. (PMID: 22173704)
J Natl Cancer Inst. 2014 Sep 10;106(9):. (PMID: 25214561)
Pharmacol Ther. 2015 Mar;147:22-31. (PMID: 25444759)
Surg Oncol. 2007 Aug;16(2):131-42. (PMID: 17719772)
Cells. 2019 Jun 26;8(7):. (PMID: 31247977)
Int J Cancer. 2011 Jul 1;129(1):256-61. (PMID: 20830713)
Onco Targets Ther. 2014 Sep 16;7:1609-17. (PMID: 25258541)
Hepatology. 2009 Mar;49(3):821-31. (PMID: 19101982)
Eur J Cancer. 2020 Mar;127:96-107. (PMID: 32004793)
Oncoscience. 2015 Aug 20;2(10):815-6. (PMID: 26682259)
Int J Cancer. 2015 Sep 15;137(6):1397-405. (PMID: 25721610)
Am J Pathol. 2001 Mar;158(3):987-96. (PMID: 11238046)
Cancer Cell Int. 2017 Jan 5;17:6. (PMID: 28070168)
Med Oncol. 2015 Jan;32(1):430. (PMID: 25491143)
Am J Pathol. 2008 Nov;173(5):1518-27. (PMID: 18832571)
Br J Cancer. 2010 Mar 16;102(6):1032-6. (PMID: 20197769)
Curr Opin Oncol. 2017 Jul;29(4):268-274. (PMID: 28489620)
Int J Mol Sci. 2020 Apr 10;21(7):. (PMID: 32290245)
Head Neck. 2017 Nov;39(11):2283-2292. (PMID: 28815787)
Int J Cancer. 2016 Aug 15;139(4):890-8. (PMID: 26950035)
J Clin Oncol. 2012 Feb 10;30(5):525-32. (PMID: 22253462)
Histol Histopathol. 2008 Jan;23(1):117-26. (PMID: 17952864)
J Surg Oncol. 2017 Nov;116(6):716-721. (PMID: 28570749)
Dev Biol. 2011 Sep 1;357(1):259-68. (PMID: 21736876)
Nat Rev Cancer. 2004 Jun;4(6):448-56. (PMID: 15170447)
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34. (PMID: 20490631)
Oncology. 2011;81 Suppl 1:24-9. (PMID: 22212932)
Ann Oncol. 2012 Mar;23(3):562-569. (PMID: 21859899)
Clin Chem. 2013 Jan;59(1):110-8. (PMID: 23014601)
Cancer Res. 2010 Oct 1;70(19):7690-8. (PMID: 20841474)
Front Oncol. 2019 Nov 18;9:1248. (PMID: 31803621)
فهرسة مساهمة: Keywords: TGF-βRI expression; beta catenin expression; circulating tumor cells; desmoid tumor; vimentin expression
تواريخ الأحداث: Date Created: 20211001 Latest Revision: 20220427
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8476862
DOI: 10.3389/fonc.2021.622626
PMID: 34595102
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2021.622626